Trending...
- California: Governor Newsom launches first new conservancy in 15 years to accelerate progress at the Salton Sea - 153
- Art In Stone, a 40-Year Bay Area Monument Leader, Launches Newly Renovated Website - 118
- InterMountain Management Announces the Re-opening of Holiday Inn Express & Suites Alexandria
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
Contacts
Chris Lewis
Sr. Director, Investor Relations & Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
- 'Into the Cole: A Tribute to Nat King Cole' Arrives at Catalina Jazz Club starring Aaron Akins
- Free Home Improvement Expo Returns to Long Beach on May 30
- Spring Into Your New Home at Heritage at South Brunswick
- UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
Contacts
Chris Lewis
Sr. Director, Investor Relations & Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
Filed Under: Business
0 Comments
Latest on The Californer
- Anglepoint named a Customers' Choice in the 2026 Gartner Peer Insights Voice of the Customer
- Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
- SYOKAMI Launches 15-Piece Magnetic Knife Set Featuring a Detachable Steak Block and Built-In Sharpener
- A3 Analytics Collaborates with PacBio to Reduce Downtime with AI Troubleshooting
- Plaza Mexico Celebrates 'Festival Día del Niño'
- GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
- 5 Things to Check Before Calling for AC Repair in Philly
- Go Dental Clinic Announces Upcoming Opening of New Branch in International City, Dubai
- DJIUSA Kicks Off Big April Sale With Discounts on DJI's Gimbal Camera Lineup
- Newport Harbor Football Opens 2026 Season in Hawaii with Special Return to the Islands
- Governor Newsom delivers $520 million in utility bill relief to millions of Californians with more coming this summer
- Tax Day Reminder: California pays Trump's bills
- Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
- Rachel Farris, CPA Named to CPA Practice Advisor 40 Under 40 List
- Rachel Farris Named to Forbes 2026 Best-In-State CPAs List
- Promoting Health One Item at a Time
- Ali Uyanik Joins Snell & Wilmer Palo Alto Office as Counsel
- Long Beach: City Announces Second Round of Backyard Builders Loan Program to Help Lower-Income Homeowners Build ADUs
- National Award: Workforce Development Board Ventura County Honored with 2026 WIOA Trailblazer Award
- Southland Symphony Orchestra Celebrates Season Finale with Dvořák, Brahms, and Guest Cellist Ruslan Biryukov